Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma

BACKGROUND: Lenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and to identify factors associated with decreased lenvatinib adherence. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Tateai, Yoshikazu, Kawakami, Kazuyoshi, Teramae, Minori, Fukuda, Naoki, Yokokawa, Takashi, Kobayashi, Kazuo, Shibata, Naoki, Suzuki, Wataru, Shimizu, Hisanori, Takahashi, Shunji, Ozaka, Masato, Sasahira, Naoki, Hori, Satoko, Yamaguchi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653419/
https://www.ncbi.nlm.nih.gov/pubmed/37972015
http://dx.doi.org/10.1371/journal.pone.0294320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653419/
https://www.ncbi.nlm.nih.gov/pubmed/37972015
http://dx.doi.org/10.1371/journal.pone.0294320

Ejemplares similares